Registration Dossier

Toxicological information

Acute Toxicity: oral

Currently viewing:

Administrative data

Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
weight of evidence
Reliability:
4 (not assignable)
Rationale for reliability incl. deficiencies:
documentation insufficient for assessment

Data source

Reference
Reference Type:
other company data
Title:
Unnamed
Year:
1975
Report date:
1976

Materials and methods

Principles of method if other than guideline:
The sample was applied to rats in CMC aqueous solution. After substance administration, the symptoms were observed for 14 days.
GLP compliance:
no
Remarks:
pre GLP
Test type:
standard acute method

Test material

Constituent 1
Chemical structure
Reference substance name:
Trisodium bis[3-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]-4-hydroxy-5-nitrobenzenesulphonato(3-)]chromate(3-)
EC Number:
260-892-4
EC Name:
Trisodium bis[3-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]-4-hydroxy-5-nitrobenzenesulphonato(3-)]chromate(3-)
Cas Number:
57674-14-3
Molecular formula:
C32H20CrN10O14S2.3Na
IUPAC Name:
trisodium bis[3-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]-4-hydroxy-5-nitrobenzenesulphonato(3-)]chromate(3-)

Test animals

Species:
rat

Administration / exposure

Route of administration:
oral: unspecified
Vehicle:
CMC (carboxymethyl cellulose)
Details on oral exposure:
Aqueous suspension of 0.5 % CMC
Details on study design:
- Duration of observation period following administration: 14 days.
- Necropsy of survivors performed: yes

Results and discussion

Effect levels
Dose descriptor:
LD50
Effect level:
7 000 other: mg/kg
Based on:
test mat.
Clinical signs:
Dyspnoea, apathy, prone position, systemic skin discoloration, urine and feces red coloured, dehydration, poor general condition, initially slight weight loss.
Gross pathology:
Acute cardiac dilatation both sides, acute hyperaemia, mucosa in the glandular stomach astringent, fatty tissue dyed.

Applicant's summary and conclusion

Interpretation of results:
other: Not classified according to the CLP Regulation
Conclusions:
LD50 oral was stated at 7000 mg/kg
Executive summary:
Method

The sample was applied to rats in CMC aqueous solution. After substance administration, the symptoms were observed for 14 days.

 

Results

LD50 oral was stated at 7000 mg/kg.

Dyspnoea, apathy, prone position, systemic skin discoloration, urine and feces red coloured, dehydration, poor general condition, initially slight weight loss were observed. Furthermore, the gross analyses revealed acute cardiac dilatation both sides, acute hyperaemia, mucosa in the glandular stomach astringent, fatty tissue dyed.